This protocol is specific to children and adolescents under 18 years of age presenting with prolactinoma. Managing prolactinoma in this age group requires careful attention: younger patients carry a heightened probability of adverse effects from treatment, which directly shapes how therapy is approached and titrated.
The full protocol provides a structured, evidence-based pathway tailored to this age group. When certain clinical criteria are met, the approach may involve radiation therapy — but the complete algorithm, selection criteria, and sequencing are contained in the full protocol.
DOI: 10.1038/s41574-023-00886-5
Dopamine agonist therapy is initiated at low doses (for example, 0.25 mg per week of cabergoline) (weak), with slow dose increases due to increased probability of adverse effects in children (strong).
Radiation therapy should be limited to patients with an aggressive adenoma that is unresponsive to dopamine agonist therapy and surgery (weak).
View source ↗